Cardiovascular Devices - Europe Pipeline Product Analysis - Stage, Indication And Estimated Approval Date
M2 - Mon Jun 16, 6:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xdmzk9/cardiovascular) has announced the addition of the "Cardiovascular Devices - Europe Pipeline Product Analysis - Stage, Indication And Estimated Approval Date" report to their offering. This report consists of the entire process involved in making of a Cardiovascular Device. Right from Early Development stage through Pre-Clinical to Clinical trails and the Approval Process is also covered in this report. This report includes a total of 91 companies with 182 products in development. This report provides Pipeline Analysis of Cardiovascular devices developed by several medical device companies located in Europe. This report includes a detailed company profile for each medical device company operating in Europe. The company profile includes key company facts, information on business description, mission statement and its location. Moreover, this report provides detailed analysis of all pipeline products of each company with information on the product category, indication, development stage, estimated approval date and pipeline territory of the product. Cardiovascular Device areas covered in this report include: - Cardiac Assist Devices - Cardiovascular Monitoring and Diagnostic Devices - Cardiac Rhythm Management Devices - Cardiovascular Surgery Devices - Electrophysiology Devices - Interventional Cardiology Devices - Peripheral Vascular Devices Transcatheter Heart Valves Why buy the report? - Develop strategies for market entry and expansion. - Identify your competition's product portfolio and create effective strategies to gain competitive advantage. - Design and develop business strategies by understanding current trends and developments. - Identify the status and estimated approval of your competitor's pipeline products and develop your business strategies. Companies Mentioned: - AFreeze GmbH - AVIDAL Vascular GmbH - Aachen Resonance GmbH - Acarix A/S - Acrostak (Schweiz) AG - Aeon Scientific AG - Andramed GmbH - Anethon - AorTech International plc - Arterion AB - Arterius Ltd - B. Braun Melsungen AG - Bayer HealthCare AG - Berlin Heart GmbH - ICON plc - IRAMED GmbH - Imaxdi - Imaxdi. - Impulse Dynamics N.V. - Inserm Transfert SA - International Biomedical Systems S.p.A. - JenaValve Technology GmbH - Leman Cardiovascular - Leukocare AG - MaRVis Technologies GmbH - Maestro Heart SA - Microstim GmbH - iVascular S.L. - iiTech BV For more information visit http://www.researchandmarkets.com/research/xd...iovascular
Cardiovascular Devices - Europe Clinicals Pipeline Product Analysis
M2 - Mon Jun 16, 6:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bbc87m/cardiovascular) has announced the addition of the "Cardiovascular Devices - Europe Clinicals Pipeline Product Analysis" report to their offering. This report provides Pipeline Analysis of Clinical Cardiovascular devices developed by several medical device companies located in Europe. This report includes a total of 52 companies with 120 products in development. This report includes a detailed company profile for each medical device company operating in Europe. The company profile includes key company facts, information on business description, mission statement and its location. Moreover, this report provides detailed analysis on all pipeline products of each company with information on the product category, indication, development stage, estimated approval date and pipeline territory of the product. Cardiovascular Device areas covered in this report include: - Cardiac Assist Devices - Cardiovascular Monitoring and Diagnostic Devices - Cardiac Rhythm Management Devices - Cardiovascular Surgery Devices - Electrophysiology Devices - Interventional Cardiology Devices - Peripheral Vascular Devices - Transcatheter Heart Valves This report is built using data and information from in-house analysis by the team of industry experts at Mordor Intelligence and from primary & secondary research. Why buy the report? - Develop strategies for market entry and expansion. - Identify your competition's product portfolio and create effective strategies to gain competitive advantage. - Design and develop business strategies by understanding current trends and developments. - Identify the status and estimated approval of your competitor's pipeline products and develop your business strategies. Companies Mentioned: - AFreeze GmbH - AVIDAL Vascular GmbH - Aachen Resonance GmbH - Acrostak (Schweiz) AG - Andramed GmbH - AorTech International plc - Arterion AB - B. Braun Melsungen AG - Carmat SAS - CellProthera - Dipylon Medical AB - Eurocor GmbH - Evasc Medical Systems - HighLife SAS - I.B.S. S.p.A. - ICON plc - Imaxdi. - Impulse Dynamics N.V. - Qvanteq AG - SAS Cormove - Sorin S.p.A. - Stentys, S.A - Symetis AG - Tioga Ltd - Tissue Regenix Ltd - Transcatheter Technologies GmbH - TrusTECH For more information visit http://www.researchandmarkets.com/research/bb...iovascular
Transcatheter Heart Valve Market Outlook, 2013
M2 - Mon Jun 10, 3:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3w68nx/transcatheter) has announced the addition of the "Transcatheter Heart Valve Market Outlook, 2013 - Approval of Second Generation Prosthetics and Increasing Surgeons' Confidence and Proficiency to Drive TAVR Procedure Volumes" report to their offering. Newcomer US to Dominate Global Transcatheter Heart Valve Market by 2017 Despite only entering the market in late 2011 with Edwards Lifesciences' Sapien, the US looks set to dominate the global Transcatheter Heart Valve (THV) market in the near future, according to business intelligence provider GBI Research. The firm's latest report* forecasts the number of Transcatheter Aortic Valve Replacement (TAVR) procedures in the US to climb from 7,946 in 2012 to 59,000 in 2017, driving the country's THV market from $238m to $1.9 billion during the same period. GBI Research states that, within one year, the US has managed to become the biggest country for THV sales, accounting for 28% of the glo
MediPoint: Transcatheter Aortic Valve Replacement - Analysis and Market Forecast - European Markets
M2 - Mon Mar 11, 5:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8kfr86/medipoint) has announced the addition of GlobalData's new report "MediPoint: Transcatheter Aortic Valve Replacement - Analysis and Market Forecast - European Markets" to their offering. This report is a vital source of up-to-date information with in-depth analysis on the rapidly growing Transcatheter Aortic Valve Replacement (TAVR) Device Market in France, Germany, Italy, Spain and the UK (EU). Provided within is a comprehensive breakdown of opportunities and inhibitors within the major EU TAVR markets, highlighting testimonials from top physicians from around the world utilizing this technique already. The report identifies and analyzes the key trends shaping and driving the EU Transcatheter Aortic Valve Replacement Market. Future EU sales expectations are discussed through careful analysis of the Transcatheter Aortic Valve Replacement procedure adoption patterns. The report provides insight into the competitive TAVR landscape in the
MediPoint: Transcatheter Aortic Valve Replacement - Analysis and Market Forecast - US Market
M2 - Mon Mar 11, 5:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/brtjc6/medipoint) has announced the addition of GlobalData's new report "MediPoint: Transcatheter Aortic Valve Replacement - Analysis and Market Forecast - US Market" to their offering. This report is a vital source of up-to-date information with in-depth analysis on the rapidly growing Transcatheter Aortic Valve Replacement (TAVR) Device Market in the US. Provided within is a comprehensive breakdown of opportunities and inhibitors within the US TAVR market, highlighting testimonials from top physicians from around the world utilizing this technique already. The report identifies and analyzes the key trends shaping and driving the US Transcatheter Aortic Valve Replacement market. Future US sales expectations are discussed through careful analysis of the Transcatheter Aortic Valve Replacement procedure adoption patterns. The report provides insight into the competitive TAVR landscape in the US, including new companies entering the market and p
MediPoint: Transcatheter Aortic Valve Replacement - Current and Future Players
M2 - Thu Mar 07, 5:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/7vv95q/medipoint) has announced the addition of GlobalData's new report "MediPoint: Transcatheter Aortic Valve Replacement - Current and Future Players" to their offering. This report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Transcatheter Aortic Valve Replacement (TAVR) Device Market. The report identifies and analyses the key companies shaping and driving the global Transcatheter Aortic Valve Replacement market. The report provides insight into the competitive TAVR landscape, including new companies entering the market and pipeline products in development. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by a team of industry experts. Scope - Investigation of current and future market competition for Transcatheter Aortic Valve Replacement, otherwise known as Transcatheter Aortic Valve Implantatio
MediPoint: Transcatheter Aortic Valve Replacement - Analysis and Market Forecast
M2 - Mon Feb 04, 8:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/94t355/medipoint) has announced the addition of GlobalData's new report "MediPoint: Transcatheter Aortic Valve Replacement - Analysis and Market Forecast" to their offering. New Aortic Valve Devices May Hold the Key to Your Heart Open heart surgery may be a dying art, as new valve replacement techniques offer life-changing treatment without the need for invasive procedures, states a new report by healthcare experts The authors. The new report* studies Transcatheter Aortic Valve Replacement (TAVR), which allows the percutaneous treatment of severe Aortic Valve Disease (AVD) through the implantation of a prosthetic aortic valve within the diseased native valve without the need for open heart surgery or cardiopulmonary bypass. Rob Littlefield, MSc., The authors's analyst for cardiovascular devices, states: "AVD affects over 3.6% of the population older than 65, and severe cases of it have mortality rates of nearly 50% at two years. However,